Protalix Biotherapeutics Inc (NYSEMKT:PLX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Thursday. They presently have a $5.00 price objective on the stock.

Separately, Zacks Investment Research downgraded Protalix Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th.

Protalix Biotherapeutics (NYSEMKT:PLX) opened at $0.69 on Thursday. Protalix Biotherapeutics has a twelve month low of $0.26 and a twelve month high of $1.51.

Protalix Biotherapeutics (NYSEMKT:PLX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the firm earned ($0.07) EPS.

TRADEMARK VIOLATION WARNING: “Protalix Biotherapeutics Inc (PLX) Stock Rating Reaffirmed by HC Wainwright” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/protalix-biotherapeutics-inc-plx-stock-rating-reaffirmed-by-hc-wainwright/1695025.html.

Several institutional investors have recently added to or reduced their stakes in PLX. Renaissance Technologies LLC boosted its position in shares of Protalix Biotherapeutics by 302.1% during the first quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock valued at $2,621,000 after buying an additional 1,448,200 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Protalix Biotherapeutics during the second quarter valued at $591,000. OxFORD Asset Management LLP purchased a new stake in shares of Protalix Biotherapeutics during the second quarter valued at $576,000. Finally, Wells Fargo & Company MN boosted its position in shares of Protalix Biotherapeutics by 14,285.7% during the first quarter. Wells Fargo & Company MN now owns 100,700 shares of the company’s stock valued at $137,000 after buying an additional 100,000 shares during the last quarter.

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action.

Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.